{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P32247",
      "entity_text" : "BRS-3",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0933" ],
      "CellType" : [ "cl:CL:0000187" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "In this study, we focused on patients simultaneously diagnosed with OB/T2D, in order to determine BRS-3 expression levels in skeletal muscle sections and to assess the effects of the BRS-3 agonist, [D-Tyr 6 -beta-Ala 11, Phe 13, Nle 14] bombesin 6-14, on glucose related processes in primary cultured myocytes.",
  "reading_complete" : "2020-08-02T13:13:11Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T13:07:08Z",
  "trigger" : "levels",
  "evidence" : [ "BRS-3 expression levels" ],
  "pmc_id" : "4356436",
  "score" : 0
}